Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis

Nursing and Health Professions

• Patient with Ulcerative Colitis 100%
• Adalimumab 83%
• Infliximab 83%
• Biological Product 66%
• Follow up 33%
• Confidence Interval 33%
• Combination Therapy 33%
• Ulcerative Colitis 33%
• Remission 33%
• Patient 33%
• Logistic Regression Analysis 16%
• Kaplan Meier Method 16%
• Treatment Outcome 16%
• Adverse Event 16%
• Proportional Hazards Model 16%
• C Reactive Protein 16%
• Tumor Necrosis Factor Inhibitor 16%
• Standard 16%
• Procedures 16%

Medicine and Dentistry

• Adalimumab 83%
• Infliximab 83%
• Biological Product 66%
• Therapeutic Procedure 50%
• Combination Therapy 33%
• Follow up 33%
• Ulcerative Colitis 33%
• Hazard Ratio 33%
• Spontaneous Remission 33%
• Adverse Event 16%
• C Reactive Protein 16%
• Logistic Regression Analysis 16%
• Kaplan Meier Method 16%
• Proportional Hazards Model 16%
• Predictive Factor 16%
• TNF Inhibitor 16%
• Liver 16%
• Head 16%
• Gut 16%

Neuroscience

• Infliximab 83%
• Adalimumab 83%
• Tumor Necrosis Factor Alpha 16%
• Regression Analysis 16%
• C-Reactive Protein 16%